Published on 24 Jan 2022 on Zacks via Yahoo Finance
Investors are always looking for stocks that are poised to beat at earnings season and Abbott Laboratories ABT may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because Abbott is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABT in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at $1.21 per share for ABT, compared to a broader Zacks Consensus Estimate of $1.18 per share. This suggests that analysts have very recently bumped up their estimates for ABT, giving the stock a Zacks Earnings ESP of +2.82% heading into earnings season.